ABOUT PHARNEXT

Pharnext is an advanced clinical stage biopharmaceutical company developing new therapeutics that simultaneously target multiple key disease pathways for severe orphan and common neurological diseases. The proprietary R&D platform of Pharnext is based on network pharmacology. It allows the development of synergistic combinations of repositioned drugs – pleodrugs – which benefit from an outstanding safety profile and IP with strong enforceability. The company’s two lead pleodrugs are PXT-3003 for the treatment of Charcot-Marie-Tooth disease type 1A (Phase 2 completed) and PXT-864 for Alzheimer’s disease (Phase 2 ongoing) and other neurologic indications (Parkinson’s disease, amyotrophic lateral sclerosis).

Latest News

PXT-3003 FEATURED AT 2015 PNS BIENNIAL MEETING
Tuesday, 30 June 2015

PXT-3003 FEATURED AT 2015 PNS BIENNIAL MEETING

Press Release (EN or FR)
SYNERGISTIC EFFECTS WITH PXT-864 IN ALZHEIMER’S DISEASE
Thursday, 08 January 2015

SYNERGISTIC EFFECTS WITH PXT-864 IN ALZHEIMER’S DISEASE

Press Release (EN or FR)
Pleotherapy Proof of Concept in CMT-1A
Thursday, 18 December 2014

Pleotherapy Proof of Concept in CMT-1A

Press Release (EN or FR)
Michel de Rosen joins Pharnext Board of Directors
Tuesday, 09 December 2014

Michel de Rosen joins Pharnext Board of Directors

Press Release (EN or FR)